作者
Chris Parker,Howard Kynaston,Adrian Cook,Noel W. Clarke,Charles Catton,William Cross,René Horsleben Petersen,Raj Persad,Cheryl Pugh,Fred Saad,John Logue,Heather Payne,Lorna C Bower,Christopher D. Brawley,Mary Rauchenberger,Maroie Barkati,David Bottomley,Klaus Brasso,Hans T. Chung,Peter Chung,R. Conroy,Alison Falconer,V. Ford,Chee Goh,Catherine Heath,Nicholas D. James,Charmaine Kim‐Sing,Ravi Kodavatiganti,Shawn Malone,Stephen Morris,Abdenour Nabid,A. Ong,Rakesh Raman,S. Rodda,Paula Wells,Jane Worlding,Wendy R. Parulekar,Mahesh Parmar,Matthew R. Sydes
摘要
Previous evidence supports androgen deprivation therapy (ADT) with primary radiotherapy as initial treatment for intermediate-risk and high-risk localised prostate cancer. However, the use and optimal duration of ADT with postoperative radiotherapy after radical prostatectomy remains uncertain.